Cargando…
Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691112/ https://www.ncbi.nlm.nih.gov/pubmed/28939993 http://dx.doi.org/10.1007/s00277-017-3129-0 |
_version_ | 1783279730667028480 |
---|---|
author | Tsutsumi, Yutaka Nakayama, Chie Kamada, Koki Kikuchi, Ryo Kudo, Daiki Ito, Shinichi Matsuoka, Satomi Shiratori, Souichi Yamamoto, Yoshiya Naruse, Hirohito Teshima, Takanori |
author_facet | Tsutsumi, Yutaka Nakayama, Chie Kamada, Koki Kikuchi, Ryo Kudo, Daiki Ito, Shinichi Matsuoka, Satomi Shiratori, Souichi Yamamoto, Yoshiya Naruse, Hirohito Teshima, Takanori |
author_sort | Tsutsumi, Yutaka |
collection | PubMed |
description | The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases of HCV-RNA-positive diffuse large-cell lymphoma. The control groups consisted of a group of HCV-RNA-positive diffuse large-cell lymphoma cases prior to this trial (control 1), and a group of cases that tested negative for HIV, HCV, and HBV (control 2). All the cases were in remission at the time of initial treatment. There were no significant differences between the three groups in terms of age, sex, treatment, stage, or International Prognosis Index (IPI). When HCV antiviral therapy was performed after treatment for diffuse large-cell lymphoma, we observed no recurrence or deaths, and the 2-year overall survival and progression-free survival rates were significantly greater than those in the control 1 group (P = 0.0246). It is possible that a better prognosis can be achieved by performing HCV antiviral therapy after achieving remission in cases of HCV-RNA-positive diffuse large-cell lymphoma through the use of R-CHOP or similar treatments. |
format | Online Article Text |
id | pubmed-5691112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-56911122017-11-30 Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma Tsutsumi, Yutaka Nakayama, Chie Kamada, Koki Kikuchi, Ryo Kudo, Daiki Ito, Shinichi Matsuoka, Satomi Shiratori, Souichi Yamamoto, Yoshiya Naruse, Hirohito Teshima, Takanori Ann Hematol Original Article The purpose of this study is to study the usefulness of post-remission antiviral therapy in cases of HCV-RNA-positive diffuse large-cell lymphoma. Antiviral therapy against HCV was performed after remission using CHOP or CHOP-like chemotherapy in combination with rituximab in five successive cases of HCV-RNA-positive diffuse large-cell lymphoma. The control groups consisted of a group of HCV-RNA-positive diffuse large-cell lymphoma cases prior to this trial (control 1), and a group of cases that tested negative for HIV, HCV, and HBV (control 2). All the cases were in remission at the time of initial treatment. There were no significant differences between the three groups in terms of age, sex, treatment, stage, or International Prognosis Index (IPI). When HCV antiviral therapy was performed after treatment for diffuse large-cell lymphoma, we observed no recurrence or deaths, and the 2-year overall survival and progression-free survival rates were significantly greater than those in the control 1 group (P = 0.0246). It is possible that a better prognosis can be achieved by performing HCV antiviral therapy after achieving remission in cases of HCV-RNA-positive diffuse large-cell lymphoma through the use of R-CHOP or similar treatments. Springer Berlin Heidelberg 2017-09-22 2017 /pmc/articles/PMC5691112/ /pubmed/28939993 http://dx.doi.org/10.1007/s00277-017-3129-0 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Tsutsumi, Yutaka Nakayama, Chie Kamada, Koki Kikuchi, Ryo Kudo, Daiki Ito, Shinichi Matsuoka, Satomi Shiratori, Souichi Yamamoto, Yoshiya Naruse, Hirohito Teshima, Takanori Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma |
title | Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma |
title_full | Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma |
title_fullStr | Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma |
title_full_unstemmed | Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma |
title_short | Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma |
title_sort | efficacy and prognosis of antiviral therapy on hepatitis c following treatment of lymphoma in hcv-positive diffuse large-cell lymphoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691112/ https://www.ncbi.nlm.nih.gov/pubmed/28939993 http://dx.doi.org/10.1007/s00277-017-3129-0 |
work_keys_str_mv | AT tsutsumiyutaka efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT nakayamachie efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT kamadakoki efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT kikuchiryo efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT kudodaiki efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT itoshinichi efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT matsuokasatomi efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT shiratorisouichi efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT yamamotoyoshiya efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT narusehirohito efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma AT teshimatakanori efficacyandprognosisofantiviraltherapyonhepatitiscfollowingtreatmentoflymphomainhcvpositivediffuselargecelllymphoma |